Contineum Therapeutics shows meaningful analyst-implied upside and bullish above-200-day-MA momentum, but a quality score far below the engine's floor, modest insider selling, and its binary-outcome biotechnology profile keep the engine's stance at exit.
Thesis pillars
- Analyst Upside Valuation↓Deteriorating
- Quality Floor Exit Signal↑Improving
- Overbought Momentum Risk↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 5, 2026
Contineum Therapeutics, Inc. (CTNM) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $9.15, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIPE-791; Market cap $344M below $400M minimum.
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation, and immunology, led by wholly-owned candidate PIPE-791, an LPA1 receptor antagonist in Phase 2 development for idiopathic pulmonary fibrosis.... Read more
Hold if already holding. Not a fresh buy at $9.15, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIPE-791; Market cap $344M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $344M below $400M minimum. Not in investable universe. Score 5.4/10, moderate confidence.
Passes 7/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA) and earnings proximity 0d<=7d. Suitability: speculative.
About Contineum Therapeutics, Inc.
About Contineum Therapeutics, Inc.
Contineum Therapeutics' wholly-owned lead asset, PIPE-791, is a brain-penetrant LPA1 receptor antagonist advancing into a Phase 2 trial for idiopathic pulmonary fibrosis that began enrolling roughly 324 subjects in December 2025, alongside a completed Phase 1b trial in chronic pain with data expected in the second quarter of 2026. The clinical-stage biopharmaceutical company partners its second program, PIPE-307, a muscarinic M1 receptor antagonist renamed JNJ-89495120, with Johnson & Johnson, which reported $7.8 billion of neuroscience drug sales in 2025.
PIPE-791 targets the LPA1 receptor pathway implicated in pulmonary fibrosis, a mechanism the company says is clinically validated by third-party trials of other LPA1R antagonists, and Contineum is positioning the drug's once-daily dosing as a tolerability advantage over the three currently approved IPF therapies, which require multiple daily doses. PIPE-307 targets major depressive disorder and relapsing-remitting multiple sclerosis; J&J began its Phase 2 Moonlight-1 trial for MDD in December 2024 and retains sole discretion over whether to continue developing the molecule for either indication. Contineum deferred further clinical development of a separate PIPE-791 progressive multiple sclerosis program and its preclinical CTX-343 program in 2025 pending additional funding, concentrating near-term spending on the IPF and chronic pain indications.
Show full overview
Contineum's two-program structure carries asymmetric risk: PIPE-307's Phase 2 VISTA trial in relapsing-remitting multiple sclerosis, reported in November 2025, showed acceptable safety but missed both its primary and secondary efficacy endpoints, and J&J holds sole discretion over whether PIPE-307 advances further in RRMS, MDD, or any other indication. That leaves wholly-owned PIPE-791 as the more direct driver of company value, with the ongoing 26-week PROPEL-IPF trial measuring forced vital capacity as its primary efficacy endpoint against three already-approved competitors, including a nerandomilast product newly approved for U.S. marketing in 2025.
See also: Healthcare · Biotechnology
From Contineum Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Contineum Therapeutics, Inc.
Latest news
- NEWS Jones Trading Maintains Buy on Contineum Therapeutics, Raises Price Target to $30 — benzinga Oct 15, 2026
- NEWS This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday — benzinga Oct 14, 2026
- NEWS Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14 — benzinga Oct 14, 2026
- NEWS 12 Health Care Stocks Moving In Monday's Intraday Session — benzinga Oct 12, 2026
- NEWS Why Is Contineum Therapeutics Stock Falling Monday? — benzinga Oct 12, 2026
Generated 2026-10-29T11:14:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinePIPE-79110-K Item 1: 'Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor ("LPA1R") in development for idiopathic pulmonary fibrosis ("IPF") and chronic pain.'
- MEDIUMcounterpartyJohnson & Johnson (PIPE-307 partner)10-K Item 1: 'J&J has sole discretion whether or not to further develop PIPE-307 for RRMS, MDD, or any other indication.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $9.15, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIPE-791; Market cap $344M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $344M below $400M minimum. Not in investable universe. Analyst target $19.26 (+110.5%), stop $8.51 (−7.5%), A.R:R 7.4:1. Score 5.4/10, moderate confidence.
Analyst target: $19.26 (+110.5% upside). Analyst target $19.26 (+110.5%), stop $8.51 (−7.5%), A.R:R 7.4:1. Stop-loss: $8.51.
Concentration risk — Pipeline: PIPE-791; Market cap $344M below $400M minimum.
Contineum Therapeutics, Inc. trades at a P/E of N/A (forward -4.7). TrendMatrix value score: 9.0/10. Verdict: Hold.
14 analysts cover CTNM with a consensus score of 4.3/5. Average price target: $22.
What does Contineum Therapeutics, Inc. do?Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for...
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for neuroscience, inflammation, and immunology, led by wholly-owned candidate PIPE-791, an LPA1 receptor antagonist in Phase 2 development for idiopathic pulmonary fibrosis. Its partnered candidate PIPE-307, licensed to Johnson & Johnson as JNJ-89495120, missed the primary and secondary efficacy endpoints of a November 2025 Phase 2 trial in relapsing-remitting multiple sclerosis, though J&J continues a separate Phase 2 trial of the drug in major depressive disorder.